| | CyberKnife Radiosurgery | External Beam Radiotherapy (EBRT) | | High-Dose-Rate (HDR) Brachytherapy | Low-Dose-Rate (LDR) Brachytherapy |
|---|--|---|---|---|--|
| | | Intensity-Modulated Radiotherapy (IMRT) | Calypso-Guided EEBRT/IMRT | riigii bose kate (ribit) braeriytiierapy | (Seed Implant) |
| ior to Treatment | | | | | |
| | Tiny gold markers (fiducials) implanted in a procedure similar to a biopsy | Tiny gold markers (fiducials) may be implanted in a procedure similar to a biopsy | Very small Calypso beacons implanted in a procedure similar to a biopsy | Ultrasound or CT scan performed to determine the prostate size prior to treatment | Ultrasound probe placed in rectum to determine prostate size and shape for pre-implant radiation pla |
| reatment Delivery | | 210207 | | | |
| Hospital Stay | No hospital stay | No hospital stay | No hospital stay | One or two hospitals stays (1 to 2 days each) | No hospital stay |
| Anesthesia | No anesthesia | No anesthesia | No anesthesia | Spinal or general anesthesia during needle/catheter placement | Spinal or general anesthesia during needle/seed placement |
| Method of delivering radiation | Concentrates 150-200 beams of radiation on prostate from numerous angles and locations | Aims 5-7 beams of radiation at prostate from a single arc | Aims 5-7 beams of radiation at prostate from a single arc | 15-20 small tubes (catheters) are inserted into the prostate to be used to deliver radiation | 20 or more needles inserted into the prostate permanently deposit about 100 radioactive seeds, which then release radiation over a period of time |
| Method of targeting/tracking | Robot automatically locates fiducials | Patient's skin is marked and therapist aligns on those marks, or targets fiducials using X-ray images | Radio-frequency detector determines beacon location. Therapist manually adjusts treatment table accordingly | Ultrasound probe placed in rectum visualizes prostate and needle/catheter position | Ultrasound probe placed in rectum visualizes prostate and needle/seed position |
| Correcting for movement | Throughout treatment robot automatically adjusts for any movement or rotation | Technician manually adjusts prior to each treatment session; no real-time correction for any movement or rotation during treatment | If movement exceeds error threshold (3 mm), treatment stops and technician manually adjusts treatment table; no correction for rotation | Physician manually places catheters using ultrasound images for guidance; a customized treatment plan accounts for variation in catheter position | Physician manually places needles using ultrasound images for guidance; no corrections possible after seeds have been implanted |
| Accuracy | One-millimeter accuracy protects surrounding tissues | Target area is expanded to include the prostate plus 5-10 millimeters to account for uncertainty | Target area is expanded to include the prostate plus approximately 5 millimeters to account for uncertainty | Custom radiation plan delivers radiation dose to within 2-3 millimeters of the target, which spares surrounding tissues | Seeds positioned with 3-5 millimeters accuracy; occasionally some seeds migrate to the lung(s) |
| Biologically equivalent radiation dose | 200 Gy (units of radiation) | 150-160 Gy (units of radiation) | 150-160 Gy (units of radiation) | 170-220 Gy (units of radiation) | 170-210 Gy (units of radiation) |
| Number/Length of Treatments | 1 treatment daily for 5 days | 1 treatment daily for 8-9 weeks | 1 treatment daily for 8-9 weeks | 1- to 2-day hospital stay, plus 5 weeks of external beam radiation therapy; or two implants with 1- to 2-day hospital stay each | Single outpatient procedure; additional 5 weeks of external beam radiation therapy may be required |
| ecovery/Side Effects | 5 | | | | |
| Side effects during/after treatment | Mild to moderate urinary problems and mild fatigue for 1-2 months; about 1% of patients need catheterization for urinary retention; resume normal activity immediately after treatment | Mild urinary and bowel problems and mild fatigue for 2 months; need for catheterization for urinary retention is rare; resume normal activity immediately after treatment | Mild urinary and bowel problems and mild fatigue for 2 months; need for catheterization for urinary retention is rare; resume normal activity immediately after treatment | Mild pain from catheters; moderate urinary problems and fatigue for 1-2 months; about 3% of patients need catheterization for urinary retention; resume normal activity 1-2 days after leaving the hospital | Pain at needle insertions; mild to severe urinary symptoms for 1-3 months; brief, mild fatigue; about 8% of patients need catheterization of urinary retention; resume normal activity day after implant |
| Long-term side effects | Despite receiving a dose similar to brachytherapy, long-term urinary effects are not common and rectal injury is rare; 20-30% patients develop erectile dysfunction | Long-term urinary and rectal injury is not common; approximately 1/3 of patients develop erectile dysfunction | Long-term urinary and rectal injury is not common; approximately 1/3 of patients develop erectile dysfunction | Occasional long-term urinary effects; rectal injury is rare; approximately 1/3 of patients develop erectile dysfunction | Frequent long-term urinary effects; rectal injury is not common; approximately 1/3 of patients develop erectile dysfunction |
| utcomes (cancer-cor | ntrol rates/freedom from PSA rise) | | | | |
| | Research at the Seattle Cyberknife Center and elsewhere are showing excellent PSA responses and low rates of recurrence. Longer follow-up is needed to confirm these findings. | 10+ year cancer-control outcomes inferior to brachytherapy; increasing the dose using image-guidance may improve results. | 10+ year cancer-control outcomes inferior to brachytherapy; increasing the dose using image-guidance Calypso may improve results. | Excellent cancer-control rates with 5-10 year follow-up | Excellent cancer control rates with 10-15 year follow- up |